KUALA LUMPUR, Malaysia, Oct. 27, 2016 /PRNewswire/ -- InClinica, a contract Clinical Research Organisation (CRO) headquartered in Philadelphia, USA and its subsidiary company, IC LifeSciences launched their Asia Pacific office in Kuala Lumpur recently. The regional office located at Menara KH will serve as a hub for clinical research and life science business development in the Asia Pacific region.
InClinica and IC LifeSciences provide an extensive range of clinical and non-clinical research services through partnerships with both local and international organisations in the pharmaceutical and biotechnology industry. Malaysia is chosen as their regional hub because of its conducive environment for research and life science advancements, apart from its ease of connectivity to the other nations in Asia Pacific.
The evening commenced with a warm welcome from Jeffrey S. Yablon, Executive Vice President of InClinica and IC LifeSciences, followed by opening remarks by Tan Sri Dato' Seri Dr. Hj. Mohd. Ismail Merican, Pro-Chancellor and Chairman of MAHSA University. About 40 guests from the research industry and academia were present to mark the occasion.
"Today's launch represents our continued growth and commitment to building a sustainable and growing organisation in the region," said Jeff Yablon. "By setting up base in Malaysia, we believe we will be able to advance the clinical research landscape via knowledge transfer and sharing. We are excited about the massive potential in the Asia Pacific region which remains untapped, and look forward to rapid progress within the next three years."
"Non-communicable diseases such as diabetes, hypertension, and obesity are rising at alarming rates in this part of the world due to industrialisation and fast-paced lifestyles. As such, clinical research is a vital aspect of medical advancement to combat these diseases and others such as infectious diseases," said Tan Sri Dr. Ismail. "We are pleased that InClinica has chosen Malaysia as its regional base, which will put us first in line in the discovery of innovative medical advancements."
InClinica also has offices in the United Kingdom, Australia and Greece. The management team boasts over 100 years of combined experience in drug and device development across diverse therapeutic areas. Through IC LifeSciences, InClinica will be collaborating with MyBioScienceLab in Malacca, which provides chemical and biological analysis for food, pharmaceuticals, nutraceuticals, medical devices and cosmetics.
About InClinica (www.inclinica.com)
InClinica, headquartered in Philadelphia, USA, is a global clinical contract research organization that works on all phases of clinical development. The company was established in 2016 following the acquisition of an existing global CRO by private equity firm, Velocity Fund Partners. InClinica is spearheaded by a management team with over 100 years of combined experience in drug and device development across diverse therapeutic areas. In addition to the U.S. and Malaysia, InClinica also has offices in the U.K., Australia, and Greece.
About IC LifeSciences
IC LifeSciences is a subsidiary company targeting global business development opportunities in the healthcare and life science industry. Founded in 2016, IC LifeSciences offers innovative science-driven products and services in multiple therapeutic areas. Currently, IC LifeSciences collaborates with testing facilities, MyBioScienceLab (Malacca) and Gateway Analytical (Pittsburgh, Pennsylvania), to provide chemical and biological analysis for food, pharmaceuticals, nutraceuticals, medical devices, and cosmetics.
